Literature DB >> 21999760

Opioid pharmacokinetic drug-drug interactions.

Brian R Overholser1, David R Foster.   

Abstract

Pharmacokinetic drug-drug interactions (DDIs) involving opioid analgesics can be problematic. Opioids are widely used, have a narrow therapeutic index, and can be associated with severe toxicity. The purpose of this review is to describe pharmacokinetic DDIs associated with opioids frequently encountered in managed care settings (morphine, codeine, oxycodone, oxymorphone, hydrocodone, hydromorphone, fentanyl, tramadol, and methadone). An introduction to the pharmacokinetic basis of DDIs is provided, and potential DDIs associated with opioids are reviewed. Opioids metabolized by the drug metabolizing enzymes of the cytochrome P450 (CYP450) system (codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone) are associated with numerous DDIs that can result in either a reduction in opioid effect or excess opioid effects. Conversely, opioids that are not metabolized by that system (morphine, oxymorphone, and hydromorphone) tend to be involved in fewer CYP450-associated pharmacokinetic DDIs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21999760

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  28 in total

Review 1.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

2.  Two cases of hallucination in elderly patients due to a probable interaction between flu immunization and tramadol.

Authors:  Paolo Pellegrino; Carla Carnovale; Cecilia Borsadoli; Tiziana Danini; Alessia Speziali; Valentina Perrone; Stefania Antoniazzi; Marco Pozzi; Emilio Clementi; Sonia Radice
Journal:  Eur J Clin Pharmacol       Date:  2013-04-25       Impact factor: 2.953

3.  Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study.

Authors:  Kelly E Dunn; Bruna Brands; David C Marsh; George E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2017-12-21       Impact factor: 4.530

Review 4.  Cytochrome P450 interactions and clinical implication in rheumatology.

Authors:  Audrey Cayot; Davy Laroche; Anne Disson-Dautriche; Anaïs Arbault; Jean-Francis Maillefert; Paul Ornetti
Journal:  Clin Rheumatol       Date:  2014-06-14       Impact factor: 2.980

Review 5.  Risks of Opioids in ST-Elevation Myocardial Infarction: A Review.

Authors:  Anne Henrieke Tavenier; Renicus Suffridus Hermanides; Jan Paul Ottervanger; Peter Gerrit Johannes Ter Horst; Elvin Kedhi; Adriaan W J van 't Hof
Journal:  Drug Saf       Date:  2018-12       Impact factor: 5.606

6.  Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury.

Authors:  Charles E Leonard; Colleen M Brensinger; Thanh Phuong Pham Nguyen; John R Horn; Sophie Chung; Warren B Bilker; Sascha Dublin; Samantha E Soprano; Ghadeer K Dawwas; David W Oslin; Douglas J Wiebe; Sean Hennessy
Journal:  Biomed Pharmacother       Date:  2020-07-30       Impact factor: 6.529

Review 7.  Perioperative Pain Management and Opioid Stewardship: A Practical Guide.

Authors:  Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary
Journal:  Healthcare (Basel)       Date:  2021-03-16

8.  Systematic review of genetic polymorphisms associated with psychoneurological symptoms in breast cancer survivors.

Authors:  Gee Su Yang; Sreelakshmy Kumar; Susan G Dorsey; Angela R Starkweather; Debra Lynch Kelly; Debra E Lyon
Journal:  Support Care Cancer       Date:  2018-10-20       Impact factor: 3.603

9.  Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgical Pain.

Authors:  Marek Brzezinski; Gregory B Hammer; Keith A Candiotti; Sergio D Bergese; Peter H Pan; Michael H Bourne; Cathy Michalsky; Linda Wase; Mark A Demitrack; Ashraf S Habib
Journal:  Pain Ther       Date:  2021-01-21

10.  Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.

Authors:  Natalie Reizine; Keith Danahey; Emily Schierer; Ping Liu; Merisa Middlestadt; Jenna Ludwig; Tien M Truong; Xander M R van Wijk; Kiang-Teck J Yeo; Monica Malec; Mark J Ratain; Peter H O'Donnell
Journal:  Oncologist       Date:  2021-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.